The Role of Interleukin-17A in Psoriatic Disease

Silvano Adami, Andrea Cavani, Francesco Rossi, Giampiero Girolomoni

Research output: Contribution to journalArticle

Abstract

The pathogenic mechanisms of specific immune-mediated inflammatory diseases (IMIDs) are not fully understood, but are thought to involve activated T cells with the release of pro-inflammatory cytokines. Understanding the autoimmune inflammatory pathways has led to the development of biological agents that target specific components of effector immune mechanisms. Despite the availability of many effective drugs, a large proportion of patients with moderate to severe IMID do not receive adequate treatment, and many therapies show decreased efficacy over time. Therefore, there is a need for new therapies. One subset of T helper cells, Th17, and the cytokine interleukin-17 (IL-17) play a central role in the pathophysiology of autoimmune diseases such as psoriasis. IL-17 is involved in the modulation of pro-inflammatory cytokines, haematopoietic growth factors, antimicrobial peptides, chemokines, and molecules involved in tissue remodelling; the inflammatory cascades triggered by Th17 cells and IL-17 itself, when unregulated, can result in widespread inflammation-related damage. Evidence of increased Th17 activity and high levels of IL-17 has been found in psoriasis, as well as other inflammatory conditions, thereby signalling the potential utility of IL-17 as a therapeutic target. Clinical trials investigating IL-17 inhibitors, such as secukinumab, in patients with psoriatic disease have reported no significant safety concerns so far. It is hoped that these agents will improve the long-term prognosis of patients with these debilitating disorders.

Original languageEnglish
Pages (from-to)487-497
Number of pages11
JournalBioDrugs
Volume28
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Interleukin-17
Cytokines
Psoriasis
Th17 Cells
Biological Factors
Therapeutics
Helper-Inducer T-Lymphocytes
Chemokines
Autoimmune Diseases
Intercellular Signaling Peptides and Proteins
Clinical Trials
Inflammation
T-Lymphocytes
Safety
Peptides
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Biotechnology
  • Medicine(all)

Cite this

Adami, S., Cavani, A., Rossi, F., & Girolomoni, G. (2014). The Role of Interleukin-17A in Psoriatic Disease. BioDrugs, 28(6), 487-497. https://doi.org/10.1007/s40259-014-0098-x

The Role of Interleukin-17A in Psoriatic Disease. / Adami, Silvano; Cavani, Andrea; Rossi, Francesco; Girolomoni, Giampiero.

In: BioDrugs, Vol. 28, No. 6, 2014, p. 487-497.

Research output: Contribution to journalArticle

Adami, S, Cavani, A, Rossi, F & Girolomoni, G 2014, 'The Role of Interleukin-17A in Psoriatic Disease', BioDrugs, vol. 28, no. 6, pp. 487-497. https://doi.org/10.1007/s40259-014-0098-x
Adami S, Cavani A, Rossi F, Girolomoni G. The Role of Interleukin-17A in Psoriatic Disease. BioDrugs. 2014;28(6):487-497. https://doi.org/10.1007/s40259-014-0098-x
Adami, Silvano ; Cavani, Andrea ; Rossi, Francesco ; Girolomoni, Giampiero. / The Role of Interleukin-17A in Psoriatic Disease. In: BioDrugs. 2014 ; Vol. 28, No. 6. pp. 487-497.
@article{5dba206468024967b4be5a88a0f37095,
title = "The Role of Interleukin-17A in Psoriatic Disease",
abstract = "The pathogenic mechanisms of specific immune-mediated inflammatory diseases (IMIDs) are not fully understood, but are thought to involve activated T cells with the release of pro-inflammatory cytokines. Understanding the autoimmune inflammatory pathways has led to the development of biological agents that target specific components of effector immune mechanisms. Despite the availability of many effective drugs, a large proportion of patients with moderate to severe IMID do not receive adequate treatment, and many therapies show decreased efficacy over time. Therefore, there is a need for new therapies. One subset of T helper cells, Th17, and the cytokine interleukin-17 (IL-17) play a central role in the pathophysiology of autoimmune diseases such as psoriasis. IL-17 is involved in the modulation of pro-inflammatory cytokines, haematopoietic growth factors, antimicrobial peptides, chemokines, and molecules involved in tissue remodelling; the inflammatory cascades triggered by Th17 cells and IL-17 itself, when unregulated, can result in widespread inflammation-related damage. Evidence of increased Th17 activity and high levels of IL-17 has been found in psoriasis, as well as other inflammatory conditions, thereby signalling the potential utility of IL-17 as a therapeutic target. Clinical trials investigating IL-17 inhibitors, such as secukinumab, in patients with psoriatic disease have reported no significant safety concerns so far. It is hoped that these agents will improve the long-term prognosis of patients with these debilitating disorders.",
author = "Silvano Adami and Andrea Cavani and Francesco Rossi and Giampiero Girolomoni",
year = "2014",
doi = "10.1007/s40259-014-0098-x",
language = "English",
volume = "28",
pages = "487--497",
journal = "Clinical Immunotherapeutics",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - The Role of Interleukin-17A in Psoriatic Disease

AU - Adami, Silvano

AU - Cavani, Andrea

AU - Rossi, Francesco

AU - Girolomoni, Giampiero

PY - 2014

Y1 - 2014

N2 - The pathogenic mechanisms of specific immune-mediated inflammatory diseases (IMIDs) are not fully understood, but are thought to involve activated T cells with the release of pro-inflammatory cytokines. Understanding the autoimmune inflammatory pathways has led to the development of biological agents that target specific components of effector immune mechanisms. Despite the availability of many effective drugs, a large proportion of patients with moderate to severe IMID do not receive adequate treatment, and many therapies show decreased efficacy over time. Therefore, there is a need for new therapies. One subset of T helper cells, Th17, and the cytokine interleukin-17 (IL-17) play a central role in the pathophysiology of autoimmune diseases such as psoriasis. IL-17 is involved in the modulation of pro-inflammatory cytokines, haematopoietic growth factors, antimicrobial peptides, chemokines, and molecules involved in tissue remodelling; the inflammatory cascades triggered by Th17 cells and IL-17 itself, when unregulated, can result in widespread inflammation-related damage. Evidence of increased Th17 activity and high levels of IL-17 has been found in psoriasis, as well as other inflammatory conditions, thereby signalling the potential utility of IL-17 as a therapeutic target. Clinical trials investigating IL-17 inhibitors, such as secukinumab, in patients with psoriatic disease have reported no significant safety concerns so far. It is hoped that these agents will improve the long-term prognosis of patients with these debilitating disorders.

AB - The pathogenic mechanisms of specific immune-mediated inflammatory diseases (IMIDs) are not fully understood, but are thought to involve activated T cells with the release of pro-inflammatory cytokines. Understanding the autoimmune inflammatory pathways has led to the development of biological agents that target specific components of effector immune mechanisms. Despite the availability of many effective drugs, a large proportion of patients with moderate to severe IMID do not receive adequate treatment, and many therapies show decreased efficacy over time. Therefore, there is a need for new therapies. One subset of T helper cells, Th17, and the cytokine interleukin-17 (IL-17) play a central role in the pathophysiology of autoimmune diseases such as psoriasis. IL-17 is involved in the modulation of pro-inflammatory cytokines, haematopoietic growth factors, antimicrobial peptides, chemokines, and molecules involved in tissue remodelling; the inflammatory cascades triggered by Th17 cells and IL-17 itself, when unregulated, can result in widespread inflammation-related damage. Evidence of increased Th17 activity and high levels of IL-17 has been found in psoriasis, as well as other inflammatory conditions, thereby signalling the potential utility of IL-17 as a therapeutic target. Clinical trials investigating IL-17 inhibitors, such as secukinumab, in patients with psoriatic disease have reported no significant safety concerns so far. It is hoped that these agents will improve the long-term prognosis of patients with these debilitating disorders.

UR - http://www.scopus.com/inward/record.url?scp=84938079964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938079964&partnerID=8YFLogxK

U2 - 10.1007/s40259-014-0098-x

DO - 10.1007/s40259-014-0098-x

M3 - Article

C2 - 24890029

AN - SCOPUS:84938079964

VL - 28

SP - 487

EP - 497

JO - Clinical Immunotherapeutics

JF - Clinical Immunotherapeutics

SN - 1173-8804

IS - 6

ER -